Chojecki, Aleksander http://orcid.org/0000-0003-2841-8321
Boselli, Danielle http://orcid.org/0000-0003-2319-3573
Dortilus, Allison
Hamadeh, Issam
Begley, Stephanie
Chen, Tommy
Bose, Rupali
Podoltsev, Nikolai
Zeidan, Amer M.
Balmaceda, Nicole Baranda
Yacoub, Abdulraheem
Ai, Jing
Knight, Thomas Gregory
Ragon, Brittany Knick
Shah, Nilay Arvind
Sanikommu, Srinivasa Reddy
Symanowski, James
Mesa, Ruben
Grunwald, Michael Richard http://orcid.org/0000-0001-5407-9875
Funding for this research was provided by:
Wake Forest University
Article History
Received: 15 January 2024
Accepted: 29 March 2024
First Online: 25 April 2024
Declarations
:
: The following relevant COI: Support for the present manuscript provided by Incyte as institutional support/ research funding, Grant number I-Rux-16-67Other disclosures directly or indirectly related to this work but reported by authors per Springer editorial policies include the following: Consulting Fees and Honoraria: Constellation Pharmaceuticals, AbbVie, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI BioPharma, Daiichi Sankyo, Gamida Cell, Genentech, Gilead, GSK/Sierra Oncology, Incyte, Invitae, Jazz, Karius, Novartis, Ono Pharmaceutical, Pfizer, Pharmacosmos, Premier, Servier/Agios, and Stemline TherapeuticsPayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Incyte, Research to Practice, Novartis, Sierra Oncology, Genentech, Sierra, Blueprint, Geron, Telios, CTI Biopharma, Incyte, BMS, Abbvie, Glaxo Smith Kline, Morphosys, Gilead, AstraZeneca, Cogen Biosciences, Abbvie, Janssen Oncology, Epizyme -honoraria or speakers bureau--Of note -- No writing support by Incyte for this manuscriptParticipation on a Data Safety Monitoring Board or Advisory Board: Novartis, Pfizer, Incyte, CTI, PharmaAstellas, Apellis, Gilead, Notable Labs, Celgene, AbbVie, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Roche, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Zentalis, Schrodinger, Regeneron, Syros, Schrodinger, Tyme, Morphosys, Pharmaessentia, Acceleron Pharma, Epizyme, Adaptive Biotechnologies, ADC Therapeutics, Genmab, TG Therapuetics, Karyopharm, Loxo/Lilly Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Novartis, Abbvie, Gilead, Syros, BioCryst, Abbvie, ALX Oncology, Kura, Geron and Celgene/BMS, Leukemia Lymphoma SocietyStock or stock options: MedtronicOther financial or non-financial interests/Institutional Research Funding: Celgene/BMS, Abbvie, Astex, Pfizer, Kura, Medimmune/AstraZeneca, Boehringer-Ingelheim, Incyte, Takeda, Novartis, Shattuck Labs, Geron, Foran, Prelude, Incyte, Kartos, and Aprea.